Jan 07, 2019 - Shares of all three cancer-focused companies shot higher after one of their peers got bought out for a sizable premium.
Oct 30, 2018 -
Oct 30, 2018 - The following slide deck was published by Blueprint Medicines in conjunction with their 2018 Q3 earnings call.
Oct 24, 2018 - Loxo Oncology (LOXO) and Blueprint Medicines (BPMC) both recently published updated results for their small molecule kinase inhibitors targeting RET altered thyroid cancer. Both companies reported inc
Oct 23, 2018 - Blueprint Medicines (BPMC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aug 17, 2018 -
May 31, 2018 - FDA Commissioner Scott Gottlieb´s remarks concerning the potential of gene therapy, bode well for stocks participating in that theme.A clinical hold for CRISPR Therapeutics caused some concern but I p
May 24, 2018 - The company has $81.5 million in cash that will be shown in the balance sheet of the next quarterly report.Taking into account the new cash, the company is trading at 2.5x its cash per share.Peers are
May 22, 2018 - Recent weakness in the biotech sector is an opportunity to add to conviction holdings.My ¨Week in Review¨ blog post appears to have the makings of a permanent feature due to positive feedback received
May 17, 2018 - Opaleye Management is a smaller fund with exceptional performance of late.Their top two holdings are heavily weighted and they are capitalizing on the targeted oncology theme as well.I provide a brief